By Adam Bonislawski

Australian diagnostics firm HealthLinx said this week that it has signed a deal with Seoul Clinical Laboratories for commercial distribution of its OvPlex ovarian cancer diagnostic in South Korea.

With the agreement, HealthLinx now has distribution deals for the protein biomarker-based test in the UK, Australia, Singapore, Israel, and South Korea, with sales of OvPlex currently ongoing in the UK, Australia, and Singapore after launches in those countries earlier this year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.